Compare NIO Inc. (NIO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Novartis AG — how do they compare? NIO Inc. trades at $3.46 (market cap $8.62B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 31.2× NIO Inc.'s market cap, and Novartis AG pays a 3.31% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Novartis AG for 82 Days on average.
| NIO | NVS | |
|---|---|---|
Market Cap | $8.62B | $268.57B |
Volume | 39,648,517 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $168.62 |
52-Week Low | $3.37 | $121.80 |
Typical Hold Time | 81 Days | 82 Days |
Enterprise Value | $6.52B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.54, down 55% from its 52-week high, with a bearish technical signal despite recent earnings beats. The company shows improving revenue growth (2025: $87.5B) and narrowing losses (net margin: -17.8% in 2025 vs -34.5% in 2024), supported by a strategic battery-swap partnership with Geely. However, negative cash flow (-$10.9B in 2024) and high debt ($20.6B total debt) remain concerns.
The stock offers speculative upside to the $6.23 analyst target (76% potential) but faces significant execution risks in China's competitive EV market. Investors must weigh improving fundamentals against persistent profitability challenges and macroeconomic headwinds.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
